207297-08-3

Basic information

• Product Name: N-hydroxy-4-hydroxy-benzenecarboximidoyl chloride
• Synonyms: N-hydroxy-4-hydroxy-benzenecarboximidoyl chloride
• CAS NO: 207297-08-3
• Molecular Weight: 171.583
• Mol File: 207297-08-3.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: N-hydroxy-4-hydroxy-benzenecarboximidoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-hydroxy-4-hydroxy-benzenecarboximidoyl chloride(207297-08-3)
• EPA Substance Registry System: N-hydroxy-4-hydroxy-benzenecarboximidoyl chloride(207297-08-3)

Safety Data

• Hazardous Substances Data: 207297-08-3(Hazardous Substances Data)

Upstream product

• 699-06-9 4-hydroxybenzaldehyde oxime 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 941674-32-4 (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazoleacetic acid 
• 478336-92-4 methyl 2-(3-(4-hydroxyphenyl)-4,5-dihydroisoxazol-5-yl)acetate 
• 1352954-67-6 C₂₄H₂₄N₂O₇ 
• 440115-82-2 4-hydroxy-benzonitrile N-oxide 
• 1071788-87-8 ethyl 3-(4-hydroxyphenyl)-5-methylisoxazole-4-carboxylate 
• 1610930-39-6 p-hydroxy-O,O'-bis(tert-butyldimethylsilyl)-N,N’-dihydroxybenzamidine 
• 1605302-44-0 p-hydroxy-O,O'-bis(tetrahydropyran-2-yl)-N,N'-dihydroxybenzamidine 
• 1605302-37-1 p-hydroxy-O,O'-dibenzyl-N,N'-dihydroxybenzamidine 
• 1605302-31-5 p-hydroxy-O-benzyl-N,N'-dihydroxybenzamidine 

Relevant articles and documents

Design, synthesis, in vitro and in silico evaluation of new 3-phenyl-4,5-dihydroisoxazole-5-carboxamides active against drug-resistant mycobacterium tuberculosis

A new series of 3-phenyl-4,5-dihydroisoxazole-5-carboxamides were designed, synthesized, and evaluated for their potency against Mtb H37Rv. Designed molecules were synthesized by one-pot cycloaddition reaction in good to excellent yields. Anti-Tubercular evaluation of all synthesized derivatives identified 6k to be highly potent (MIC 1 μg/mL) against Mtb and drug-resistant strains. All potent derivatives were found to be non-toxic when tested against Vero cells. Also, in silico studies were employed to explore the binding patterns of designed compounds to target Mycobacterial membrane protein Large-3. All derivatives exhibited excellent binding patterns with the receptor. The excellent in silico Absorption, Distribution, Metabolism, and Excretion properties and druggability parameters positions these molecules as promising lead candidates for the future development of new drugs to treat drug-resistant Tuberculosis.

Design, docking and synthesis of novel bromo isatin incorporated isoxazole derivatives as vegfr-2 inhibitors

Objective: To design, synthesize, in vitro Vascular Endothelial Growth Factor Receptor (VEGFR-2) assay, antiproliferative activity an Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) studies of some novel bromoisatin incorporated isoxa

Constructing novel dihydrofuran and dihydroisoxazole analogues of isocombretastatin-4 as tubulin polymerization inhibitors through [3+2] reactions

[3+2] reactions play a key role in constructing various pharmaceutical moleculars. In this study, using Mn(OAc)3 mediated and 1,3-dipolar [3+2] cyclization reactions, 38 novel dihydrofuran and dihydroisoxazole analogues of isoCA-4 were synthesized as inhibitors of tubulin polymerization. Among them, compound 6g was found to be the most potent cytotoxic agents against PC-3 cells with IC50 value of 0.47 μM, and compound 5p exhibted highest activity on HeLa cells with IC50 vaule of 2.32 μM. Tubulin polymerization assay revealed that 6g was a dose-dependent and effective inhibitor of tubulin assembly. Immunohistochemistry studies and cell cycle distribution analysis indicated that 6g severely disrupted microtubule network and significantly arrested most cells in the G2/M phase of the cell cycle in PC-3 cells. In addition, molecular docking studies showed that two chiral isomers of 6g can bind efficiently and similarly at colchicine binding site of tubulin.